Taiwan FDA Approval number:060827

Package Insert Download (English Version)

You are encouraged to report negative side effects of prescription drugs to:



FESPIXON ®Clinical Information:
-NCT04962139 (click here for the ongoing phase 3 clinical trail)
-NCT01898923 (click here for the compeleted phase 3 clinical trail)

Residents in the United States may join the Phase 3 clinical trial or apply for the use of Fespixon (ON101) via the licensed physician under the Expanded Access Program. For more information, please visit NCT04962139 on clinicaltrials.gov or the EAP page.